Calithera Biosciences, Inc. (NASDAQ:CALA) [Trend Analysis] plunged reacts as active mover, shares a loss -4.11% to traded at $3.50 and the percentage gap between open changing to regular change was -2.74%. Bristol-Myers Squibb Company (BMY) and Calithera Biosciences, Inc. (CALA) reported a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivoin combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC).
The companies will explore the potential of combining these two agents with the goal of achieving improved and sustained efficacy in ccRCC patients with cancer that is stable or growing on a PD-1 inhibitor therapy.CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies. The firm’s current ratio calculated as 12.20 for the most recent quarter. The firm price to cash ratio remained 1.39. As far as the returns are concern, the return on equity was recorded as -58.20%. The firm has total debt to equity ratio measured as 0.00.
BB&T Corporation (NYSE:BBT) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.19% to close at $47.31 with the total traded volume of 3.54 Million shares. BB&T Corporation (BBT) reported that Chris Henson has been named president, BB&T Corporation, and president, Branch Banking and Trust Company. The announcement is effective immediately.As president and chief operating officer, Henson oversees many of BB&T’s core businesses including Data and Technology Services; Deposit, Payment and Operations Services; Enterprise Digital Strategy; Enterprise Marketing, Sales and Experience Group; Financial Services; Human Systems; Legal; Insurance Services; Mortgage and BB&T’s Specialized Lending subsidiaries. In 2017, he will also oversee BB&T’s Community Banking division, following the retirement of Ricky Brown. Henson will continue to report to Chairman and Chief Executive Officer Kelly S. King. The firm has institutional ownership of 64.80%, while insider ownership included 0.10%. Its price to sales ratio ended at 5.53. BBT attains analyst recommendation of 2.50 with week performance of 1.33%.